Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

NCT04521296 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

432

Enrollment

INDUSTRY

Sponsor class

Stopped Changes in drug development plans

Conditions

Mild to Moderate COVID-19

Interventions

OTHER: Part 1
OTHER: Part 2

Sponsor

Daewoong Pharmaceutical Co. LTD.